Score Overview
Explore the 2021 public Archive ranking →
Where Aurinia Pharmaceuticals Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- AUPH
2010: 98.1% · 2021: 98.8% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-09 | $ 16.65 | — |
1 Year2025-10-09 | $ 11.62 | 43.29% |
5 Years2021-10-08 | $ 19.33 | -13.86% |
10 Years2016-10-07 | $ 4.70 | 254.26% |
20 Years2006-09-29 | $ 54.12 | -69.24% |
| Period | Last Price2026-10-09 | 1 Year2025-10-09 | 5 Years2021-10-08 | 10 Years2016-10-07 | 20 Years2006-09-29 |
|---|---|---|---|---|---|
| Price | $ 16.65 | $ 11.62 | $ 19.33 | $ 4.70 | $ 54.12 |
| Return | — | 43.29% | -13.86% | 254.26% | -69.24% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 311M | $ 314M | $ 443M |
| 2025 | $ 283M | $ 287M | $ 397M |
| 2024 | $ 235M | $ 5M | $ 358M |
| 2023 | $ 175M | -$ 78M | $ 350M |
| 2022 | $ 134M | -$ 108M | $ 389M |
| 2021 | $ 45M | -$ 180M | $ 466M |
| 2020 | $ 50M | -$ 102M | $ 398M |
| 2019 | -$ 88M | $ 306M | |
| 2018 | $ 463K | -$ 64M | $ 125M |
| 2017 | $ 420K | -$ 70M | $ 173M |
| 2016 | $ 173K | -$ 23M | $ 39M |
| 2015 | $ 235K | -$ 18M | $ 15M |
| 2014 | $ 278K | -$ 16M | $ 32M |
| 2013 | $ 948.56K | -$ 2M | $ 1M |
| 2012 | $ 6M | -$ 9M | $ 184.96K |
| 2011 | $ 927.52K | -$ 2M | $ 5M |
| 2010 | $ 3M | -$ 3M | $ 6M |
| 2009 | $ 4M | -$ 7M | $ 4M |
| 2008 | $ 3M | -$ 15M | $ 21M |
| 2007 | $ 2M | -$ 33M | $ 32M |
| 2006 | $ 3M | -$ 22M | $ 22M |
| 2005 | $ 1M | -$ 29M | $ 45M |
| 2004 | $ 1M | -$ 22M | $ 50M |
| 2003 | $ 7M | -$ 14M | $ 62M |
| 2002 | $ 11M | -$ 365.87K | $ 40M |
| 2001 | $ 5M | -$ 7M | $ 33M |
| 2000 | $ 902.77K | -$ 6M | $ 11M |
| IPO1999 | $ 1M | -$ 1M | $ 2M |
Aurinia Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 50M to $ 283M and net income went from -$ 102M to $ 287M. Revenue increased in every one of those 5 years; net income in every one.
Between 2005 and 2025, revenue grew from $ 1M to $ 283M and net income went from -$ 29M to $ 287M. Revenue increased in 11 of those 20 years; net income in 11.
Aurinia Pharmaceuticals Inc currently holds a 20-year HDB Score of 4.8 out of 10. How the HDB Score is calculated.
Membership
Continue AUPH’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,126 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
